<table>
<thead>
<tr>
<th>Drug</th>
<th>Topical Antifungal Agents</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CNL8 Nail (ciclopirox)</td>
</tr>
<tr>
<td></td>
<td>Jublia (efinaconazole)</td>
</tr>
<tr>
<td></td>
<td>Kerydin (tavarborole)</td>
</tr>
</tbody>
</table>

**Policy #** 13118

**Indications**

- **CNL8 (ciclopirox)** external Kit, as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to *Trichophyton rubrum*.

- **Jublia** is an azole antifungal indicated for the topical treatment of onychomycosis of the toenails due to *Trichophyton rubrum* and *Trichophyton mentagrophytes*.

- **Kerydin** topical solution, 5% is an oxaborole antifungal also indicated for the treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*.

**Criteria**

ConnectiCare considers CNL8, Jublia and Kerydin medically necessary for patients who meet all of the following criteria:

- The medication must be prescribed by a Dermatologist or Podiatrist
- Patient has a diagnosis of onychomycosis
- Patient has had a treatment failure of, or intolerance to, a 3-month course of treatment with oral Lamisil (terbinafine)
- Patient has had a treatment failure of, or intolerance to, Penlac (ciclopirox)
- Patient is immunocompromised and/or diabetic

Physician documented contraindications to terbinafine include:

- Abnormal liver function tests
- Creatinine clearance ≤ 50 ml/min
- History of hepatitis or another active liver disease

**Limitations**

If the above criteria has been met, approval for any of these medications will be granted for a one-time authorization of 48 weeks.

Note: CNL8 Nail Kit contains: 3-5ml bottles of ciclopirox topical solution, 25 nail lacquer removal swabs, and 1 emery board. One CNL8 Nail Kit will last approximately 6 months and will take 3 copayments at the pharmacy.
## Pharmacy Pre-Authorization Criteria

<table>
<thead>
<tr>
<th>Drug</th>
<th>Topical Antifungal Agents #13118</th>
</tr>
</thead>
</table>
| **References** | 1. Jublia package insert, Bridgewater, NJ, Valeant Pharmaceuticals  
2. Pharmacists’ Letter, Vol: 30  
4. CNL8 full prescribing information. Charleston, SC. JSJ Pharmaceuticals |
| **P&T Review History** | 6/08, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 8/16, 8/17 |
| **Revision Record** | 9/15, 8/16, 8/17 |